RUXIENCE
Google image searchProduct monograph
Active ingredient
rituximab, 10 MG/ML
DIN: 02495724
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Description: CONCENTRATE. SINGLE USE VIAL
Schedule: Prescription / Schedule D
Company: PFIZER CANADA ULC
Date: 26-MAY-2020
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FA — CD20 (Clusters of Differentiation 20) inhibitors (ATC, ATC/DDD)
- L01FA01 — RITUXIMAB (ATC/DDD)
Reference brand drug: Rituxan, Riximyo, Ruxience, Truxima
